Regulatory authorisation is rarely the bottleneck in a DACH market entry. For an EU/EEA insurer, a freedom-of-services notification typically takes one to three months; building a distribution architecture that actually produces premium takes nine to eighteen. The correct sequence is: target segment, risk carrier, product architecture, distribution architecture — and only then the regulatory route.
Cost containment in international claims is routinely confused with after-the-fact discount negotiation. That is not only the weakest lever — it is the legally weakest one. The insurer is not a party to the treatment contract. Without a network agreement or a prior guarantee of payment, it has no claim against the provider; it can only reduce payment to its own policyholder, which pushes the difference onto the patient. Effective cost steering therefore happens before the invoice exists: through medical triage at first contact, care pathway steering, network contracts, and a guarantee of payment with a defined scope.
Severe Illness programmes rarely fail on product design. They fail on three elements routinely treated as procurement items: the reinsurer, the treatment network and the reporting. In this line the reinsurer is effectively a co-designer and the price-setter, because no own experience exists. The network is not an added service but the product itself — without centres that can actually treat the conditions, all that remains is a promise to pay. And reporting must produce leading indicators, because a Severe Illness book is statistically almost invisible in its first two years. If any one pillar is missing, the programme does not hold, however well the wording is drafted.